Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 27 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2054 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing the tax inversion trend among US-based companies in the life sciences sector, Salix Pharmaceuticals has agreed to buy the Ireland-domiciled subsidiary of Italian speciality pharmaceutical company Cosmo Pharmaceuticals in an all-stock deal valued at approximately US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS